EUCTR2017-002840-34-PL进行中（未招募）1 期
An open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are judged by the investigator to benefit from continued treatment with osilodrostat
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Recordati AG
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Currently participating in a Global Novartis-sponsored osilodrostat study
- •2. Currently benefiting from treatment with osilodrostat, as determined by the Investigator
- •3. Demonstrated compliance, as assessed by the Investigator, with the parent study protocol requirements
- •4. Willingness and ability to comply with scheduled visits and treatment plans
- •5. Written informed consent obtained prior to enrolling into the roll-over study
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 5
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 170
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •1. Permanently discontinued from osilodrostat study treatment in a parent Novartis-sponsor study
- •2. Receiving osilodrostat in combination with unapproved or experimental treatments for any type of endogenous CS
- •3. Pregnant or nursing women
- •4. Women of child-bearing potential, unless they are using highly effective methods of contraception during dosing and for 1 week after stopping medication
研究者
相似试验
已完成
4 期
A roll-over Study in Patients With Endogenous Cushing's SyndromeCushing's syndromeJPRN-jRCT2080224109Recordati Rare Diseases Japan K.K180
已完成
3 期
A roll-over Study in Patients With Endogenous Cushing's SyndromeJPRN-jRCT2080222646137
进行中（未招募）
1 期
A clinical trial to look at long-term safety of lenvatinib either alone or in combination with another drug, in patients with cancer.solid tumors or lymphomas, as defined in parent protocolMedDRA version: 21.1Level: PTClassification code 10055107Term: Thyroid cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10016935Term: Follicular thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10027105Term: Medullary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10066474Term: Thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 24.0Level: PTClassification code 10033701Term: Papillary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10025315Term: Lymphoma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003668-11-DEEisai Ltd.35
进行中（未招募）
1 期
A clinical trial to look at long-term safety of lenvatinib either alone or in combination with another drug, in patients with cancer.solid tumors or lymphomas, as defined in parent protocolMedDRA version: 20.0 Level: PT Classification code 10055107 Term: Thyroid cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1 Level: PT Classification code 10016935 Term: Follicular thyroid cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10027105 Term: Medullary thyroid cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10066474 Term: Thyroid cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10033701 Term: Papillary thyroid cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10025315 Term: Lymphoma malignant System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003668-11-ESEisai Ltd.35
进行中（未招募）
2 期
A Novartis- sponsored Osilodrostat (LCI699) roll over drug study to assess the long-term safety in patients with Cushings syndrome which are judged by the study doctor to receive the continued treatment of Osilodrostat (LCI699) drug.CTRI/2019/07/020063ovartis Healthcare Pvt Ltd